Samuel Kiil Sørensen

Samuel Kiil Sørensen

Auto-generated profile, based on publicly available information

Samuel Kiil Sørensen

Department of Cardiology Copenhagen University Hospital Gentofte Hellerup Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
SSSamuel K. Sørensen
Samuel K. Sørensen
AJArne Johannessen
Arne Johannessen
RWRené Worck
René Worck
MHMorten L. Hansen
Morten L. Hansen
JHJim Hansen
Jim Hansen
Background: Recurrent paroxysmal atrial fibrillation (AF) after catheter ablation is presumably caused by failure to achieve durable pulmonary vein isolation (PVI). The primary methods of PVI are radiofrequency catheter ablation (RF) and cryoballoon catheter ablation (CRYO), but these methods have not been directly compared with respect to PVI durability and the effect thereof on AF burden (% of time in AF). Methods: Accordingly, we performed a randomized trial including 98 patients (68% male, 61 [55–67] years) with paroxysmal AF assigned 1:1 to PVI by contact-force sensing, irrigated radiofrequency catheter, or second-generation cryoballoon catheter. Implantable cardiac monitors were inserted ≥1 month before PVI for assessment of AF burden and recurrence, and all patients, irrespective of AF recurrence, underwent a second procedure 4 to 6 months after PVI to determine PVI durability. Results: In the second procedure, 152 out of 199 (76%) pulmonary veins (PVs) were found durably isolated after RF and 161 out of 200 (81%) after CRYO ( P =0.32), corresponding to durable isolation of all veins in 47% of patients in both groups ( P =1.0). Median AF burden before PVI was 5.4% (interquartile range, 0.5%–13.0%) versus 4.0% (0.6%–18.1%), RF versus CRYO ( P =0.71), and reduced to 0.0% (0.0%–0.1%) and 0.0% (0.0%–0.5%), respectively ( P =0.58)—a reduction of 99.9% (92.9%–100.0%) and 99.3% (85.9%–100.0%; P =0.36). AF burden after PVI significantly correlated to the number of durably isolated PVs ( P <0.01), but 9 out of 45 (20%) patients with durable isolation of all veins had recurrence of AF within 4 to 6 months after PVI (excluding a 3-month blanking period). Conclusions: PVI by RF and CRYO produce similar moderate to high PVI durability. Both treatments lead to marked reductions in AF burden, which is related to the number of durably isolated PVs. However, for one-fifth of paroxysmal AF patients, complete and durable PVI was not sufficient to prevent even short-term AF recurrence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03805555.

24 December 2021 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
AAAndreas Andersen
Andreas Andersen
JBJonatan I. Bagger
Jonatan I. Bagger
SSSamuel K. Sørensen
Samuel K. Sørensen
Maria Pompea Antonia BaldassarreMaria Pompea Antonia Baldassarre
Maria Pompea Antonia Baldassarre
UPUlrik Pedersen-Bjergaard
Ulrik Pedersen-Bjergaard
Tina VilsbøllTina Vilsbøll
Tina Vilsbøll
Background: Insulin-treated patients with type 2 diabetes (T2D) are at risk of hypoglycemia, which is associated with an increased risk of cardiovascular disease and mortality. Using a long-term monitoring approach, we investigated the association between episodes of hypoglycemia, glycemic variability and cardiac arrhythmias in a real-life setting. Methods: Insulin-treated patients with T2D (N = 21, [mean ± SD] age 66.8 ± 9.6 years, BMI 30.1 ± 4.5 kg/m2, HbA1c 6.8 ± 0.4% [51.0 ± 4.8 mmol/mol]) were included for a one-year observational study. Patients were monitored with continuous glucose monitoring ([mean ± SD] 118 ± 6 days) and an implantable cardiac monitor (ICM) during the study period. Results: Time spend in hypoglycemia was higher during nighttime than during daytime ([median and interquartile range] 0.7% [0.7–2.7] vs. 0.4% [0.2–0.8]). The ICMs detected 724 episodes of potentially clinically significant arrhythmias in 12 (57%) participants, with atrial fibrillation and pauses accounting for 99% of the episodes. No association between hypoglycemia and cardiac arrhythmia was found during daytime. During nighttime, subject-specific hourly incidence of cardiac arrhythmias tended to increase with the occurrence of hypoglycemia (incident rate ratio [IRR] 1.70 [95% CI 0.36–8.01]) but only slightly with increasing time in hypoglycemia (IRR 1.04 [95% CI 0.89–1.22] per 5 min). Subject-specific incidence of cardiac arrhythmias during nighttime increased with increasing glycemic variability as estimated by coefficient of variation whereas it decreased during daytime (IRR 1.33 [95% CI 1.05–1.67] and IRR 0.77 [95% CI 0.59–0.99] per 5% absolute increase, respectively). Conclusions: Cardiac arrhythmias were common in insulin-treated patients with T2D and were associated with glycemic variability, whereas arrhythmias were not strongly associated with hypoglycemia. Trial registration: NCT03150030, ClinicalTrials.gov, registered May 11, 2017. https://clinicaltrials.gov/ct2/show/NCT03150030

2 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JTJacob Tønnesen
Jacob Tønnesen
MRMartin H. Ruwald
Martin H. Ruwald
JPJannik Pallisgaard
Jannik Pallisgaard
PRPeter Vibe Rasmussen
Peter Vibe Rasmussen
AJArne Johannessen
Arne Johannessen
MHMorten Lock Hansen
Morten Lock Hansen
Background: Guidelines recommend prioritizing treatment with antiarrhythmic drugs before referral of patients with atrial fibrillation to ablation, delaying a potential subsequent ablation. However, delaying ablation may affect ablation outcomes. We sought to investigate the impact of duration from diagnosis to ablation on the risk of atrial fibrillation recurrence and adverse events. Methods and Results: Using Danish nationwide registries, all patients with first‐time ablation for atrial fibrillation were identified and included from 2010 to 2018. Patients were divided into 4 groups by diagnosis‐to‐ablation time: 2.9 years (late ablation). The primary end point was atrial fibrillation recurrence after the 90‐day blanking period, defined by admission for atrial fibrillation, cardioversions, use of antiarrhythmic drugs, or repeat atrial fibrillation ablations. The secondary end point was a composite end point of heart failure, ischemic stroke, or death, and each event individually. The study cohort consisted of 7705 patients. The 5‐year cumulative incidence of atrial fibrillation recurrence in the 4 groups was 42.9%, 54.8%, 55.9%, and 58.4%, respectively. Hazard ratios were 1.20 (95% CI, 1.07–1.35), 1.29 (95% CI, 1.13–1.47), and 1.40 (95% CI, 1.28–1.53), respectively, with the early ablation group as reference. The hazard ratio for the combined secondary end point was 1.22 (95% CI, 1.04–1.44) in the late ablation group compared with the early ablation group. Conclusions: In patients undergoing ablation for atrial fibrillation, early ablation was associated with a significantly lower risk of atrial fibrillation recurrence. Furthermore, the associated risk of heart failure, ischemic stroke, or death was significantly lower in early‐compared with late‐ablation patients.

31 May 2022 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
RWRené Worck
René Worck
SSSamuel K. Sørensen
Samuel K. Sørensen
AJArne Johannessen
Arne Johannessen
MRMartin Ruwald
Martin Ruwald
MHMartin Haugdal
Martin Haugdal
JHJim Hansen
Jim Hansen
Introduction: Posterior wall isolation (PWI) added to pulmonary vein isolation (PVI) is increasingly used despite limited evidence of clinical benefit. We investigated the feasibility, durability, and efficacy of index‐procedure PVI + PWI radio frequency ablation (RFA) in patients with persistent atrial fibrillation (PeAF).Methods and Results: Twenty‐four patients with PeAF participated in the prospective PeAF‐Box study and underwent RFA with wide area circumferential ablation, roof‐ and inferior lines to achieve PVI + PWI at index procedure. Follow‐up included monitoring by an implantable cardiac monitor, esophagoscopy and mandated invasive lesion‐reassessment at 6 months. PWI was achieved at minor procedural cost in all patients following PVI. In 33% of patients a median of three ablations in the narrow zone between the center of the posterior wall (PW) and the posterior right carina was pivotal for swift achievement of PWI. At the 6‐month reassessment procedure 85% (95% confidence interval [CI]: 77%–92%) of pulmonary veins (PVs) and 46% (95% CI: 26%–67%) of PWs remained durably isolated. AF recurred in 25% and was associated with PV‐reconnection (p = .02) but not PW‐reconnection (p = .27). AF‐burden was 0% (interquartile range [IQR]: 0%–0%) overall and after recurrence 1% (IQR: 0%–7%).Conclusion: Index procedure PVI + PWI for PeAF was feasible when recognizing that limited ablation in a PW center‐to‐right‐carina zone was required in a subset of patients. Despite limited chronic PWI durability this strategy was followed by low AF‐burden. A PVI + PWI strategy appears promising in ablation for PeAF.

22 January 2023 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
SSSamuel K. Sørensen
Samuel K. Sørensen
AJArne Johannessen
Arne Johannessen
RWRené Worck
René Worck
MHMorten L. Hansen
Morten L. Hansen
MRMartin H. Ruwald
Martin H. Ruwald
JHJim Hansen
Jim Hansen

1 July 2017 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
SSSamuel Kiil Sørensen
Samuel Kiil Sørensen
JKJørgen Tobias Kühl
Jørgen Tobias Kühl
AFAndreas Fuchs
Andreas Fuchs
JNJakob Boesgaard Norsk
Jakob Boesgaard Norsk
LKLars Valeur Køber
Lars Valeur Køber
KKKlaus Fuglsang Kofoed
Klaus Fuglsang Kofoed